A Double-Blind Randomized Phase III Study Evaluating the Efficacy and Safety of Sorafenib Compared to Placebo in Locally Advanced/Metastatic RAI-Refractory Differentiated Thyroid Cancer

Trial Profile

A Double-Blind Randomized Phase III Study Evaluating the Efficacy and Safety of Sorafenib Compared to Placebo in Locally Advanced/Metastatic RAI-Refractory Differentiated Thyroid Cancer

Completed
Phase of Trial: Phase III

Latest Information Update: 06 Dec 2017

At a glance

  • Drugs Sorafenib (Primary)
  • Indications Thyroid cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms DECISION
  • Sponsors Bayer; Bayer HealthCare
  • Most Recent Events

    • 02 Dec 2017 This trial was completed in Sweden (end date: 30/08/2017), according to European Clinical Trials Database.
    • 02 Dec 2017 This trial was completed in Netherlands, according to European Clinical Trials Database.
    • 29 Nov 2017 This trial was completed in Belgium (End date: 2017-08-30), according to the European Clinical Trials Database.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top